Titre :

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Auteur(s) :

Ciron, J. [Auteur]
Audoin, B. [Auteur]
Bourre, B. [Auteur]
Brassat, D. [Auteur]
Durand-Dubief, Francoise [Auteur]
Laplaud, David [Auteur]
Maillart, E. [Auteur]
Papeix, C. [Auteur]
Vukusic, S. [Auteur]
ZEPHIR, Helene [Auteur]
Marignier, R. [Auteur]
Collongues, N. [Auteur]

Titre de la revue :

Revue neurologique

Nom court de la revue :

Rev. Neurol. (Paris)

Date de publication :

2018-03-29

ISSN :

0035-3787

Mot(s)-clé(s) :

Recommendations
Neuromyelitis optica
Guidelines
Treatment
Rituximab

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, ...
Lire la suite >There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue therapy. Nevertheless, considerable heterogeneity still exists concerning the pre-treatment work-up, the vaccinations required before and under treatment, the number and dosage of infusions, prevention of the risk of infusion-related reactions, prevention of infections under treatment, and frequency of therapeutic cycles. Thanks to a collaborative work among NMO-SD experts belonging to the NOMADMUS project, we provide here recommendations for all these topics concerning RTX use in NMO-SD.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Équipe(s) de recherche :

Neuroinflammation & Multiple Sclerosis (NEMESIS)

Date de dépôt :

2021-06-23T11:45:09Z